Do you consider anti-viral prophylaxis in patients taking JAK inhibitors who have recurrent uncomplicated Zoster infection, but would prefer not changing therapy?

This is a really good question without a clear answer. Patients on JAK inhibitors are not only at increased risk for VZV but also for recurrence. Data from Kevin Winthrop and colleagues examining the tofacitinib database revealed that patients with RA and PSA are at 10 to 20 times increased risk for...

I would agree with the above response. I run the (hitherto informal) immunomodulator associated ID clinic at our site. For those who are referred prior to initiating therapy, I also update their RZV vaccine at least one dose prior to initiating therapy. For those patients who desire or require secon...